FindMyKOL
Clinical trialNCT06404086CompletedPhase 2Interventional

RECOVER-SLEEP: Platform Protocol

NCT06404086 is a phase 2 interventional trial sponsored by Duke University. As of 21 Nov 2026, it is completed. It studies Melantonin Placebo, Melatonin, Modafinil, Modafinil Placebo and 2 more drugs in Hypersomnia, Long COVID and 2 more conditions. The registry lists an enrollment of 830 participants at 47 sites in 1 country. The registry lists a start date of 31 Jul 2024 and a primary completion date of 31 Dec 2025.

SponsorDuke University →Enrollment830HypersomniaLong COVIDLong COVID-19Sleep Disturbance
View the registry record on ClinicalTrials.gov

Key facts

Registry attributes as recorded on the ClinicalTrials.gov study record.

Key facts for NCT06404086
FieldValue
Registry IDNCT06404086
StatusCompleted
PhasePhase 2
Study typeInterventional trial
Lead sponsorDuke University
Enrollment830
Registered sites47
Countries1
ConditionsHypersomnia, Long COVID, Long COVID-19 and Sleep Disturbance
DrugsMelantonin Placebo, Melatonin, Modafinil, Modafinil Placebo, Solriamfetol and Solriamfetol Placebo
Start31 Jul 2024
Primary completion31 Dec 2025
Study completion31 Dec 2025
Last update posted22 Jan 2026

Registered summary

The lay summary the sponsor registered on ClinicalTrials.gov.

The platform protocol is designed to be flexible so that it is suitable for a range of study settings and intervention types. Therefore, the platform protocol provides a general protocol structure that can be shared by multiple interventions and allows comparative analysis across the interventions. For example, objectives, measures, and endpoints are generalized in the platform protocol, but intervention-specific features are detailed in separate appendices. This platform protocol is a prospective, multi-center, multi-arm, randomized controlled platform trial evaluating potential interventions for PASC-mediated sleep disturbances. The hypothesis is that symptoms of sleep and circadian disorders that emerge in patients with PASC can be improved by phenotype-targeted interventions. Specific sleep and circadian disorders addressed in this protocol include sleep-related daytime impairment (referred to as hypersomnia) and complex PASC-related sleep disturbance (reflecting symptoms of insomnia and sleep-wake rhythm disturbance).

Investigators

The overall officials registered on this study. Names that resolve to a FindMyKOL profile link to it; the rest are shown as registered.

A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.

Sites

47 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.

Arizona, United States3 sites
  • Banner University Medical Center Phoenix

    Phoenix

  • the Southern Arizona Va Health Care System

    Tucson

  • University of Arizona Banner Medical Center

    Tucson

California, United States2 sites
  • Stanford University

    Palo Alto

  • University of California San Francisco General Hospital

    San Francisco

Colorado, United States2 sites
  • University of Colorado Anschutz Medical Campus

    Aurora

  • Denver Health and Hospital Authority

    Denver

District of Columbia, United States1 site
  • Howard University Hospital

    Washington D.C.

Florida, United States2 sites
  • University of Florida College of Medicine Jacksonville

    Jacksonville

  • Lakeland Regional Medical Center

    Lakeland

Georgia, United States5 sites
  • Emory University

    Atlanta

  • Grady Memorial Hospital

    Atlanta

  • Morehouse School of Medicine

    Atlanta

  • Atlanta Va Medical Center

    Decatur

  • Emory Hope Clinic

    Decatur

Illinois, United States6 sites
  • Cook County Health Specialty Care Center

    Chicago

  • Northwestern Memorial Hospital

    Chicago

  • Rush University Medical Center

    Chicago

  • University of Illinois at Chicago

    Chicago

  • Northshore Medical Group

    Evanston

  • Saint Francis Medical Center

    Peoria

Kansas, United States1 site
  • University of Kansas Medical Center

    Kansas City

Kentucky, United States1 site
  • University of Kentucky

    Lexington

Maryland, United States2 sites
  • Johns Hopkins Bayview Medical Center

    Baltimore

  • Jadestone Clinical Research, Llc

    Silver Spring

Massachusetts, United States6 sites
  • Beth Israel Deaconess Med. Ctr.

    Boston

  • Boston Medical Center

    Boston

  • Brigham and Womens Hospital

    Boston

  • Massachusetts General Hospital

    Boston

  • Tufts Medical Center

    Boston

  • University of Massachusetts Memorial Medical Center

    Worcester

New Jersey, United States1 site
  • Rutgers University - Robert Wood Johnson Medical School

    New Brunswick

New Mexico, United States1 site
  • University of New Mexico

    Albuquerque

New York, United States1 site
  • Icahn School of Medicine at Mount Sinai

    New York

North Carolina, United States1 site
  • East Carolina University

    Greenville

Ohio, United States2 sites
  • University of Cincinnati Medical Center

    Cincinnati

  • University Hospitals of Cleveland Medical Center

    Cleveland

Oregon, United States1 site
  • Oregon Health and Science University

    Portland

Texas, United States4 sites
  • Southwest Family Medicine Associates

    Dallas

  • Houston Methodist Hospital

    Houston

  • New Dawn Wellness and Medical Research Center

    Houston

  • University of Texas Health Science Center at Houston

    Houston

Virginia, United States1 site
  • University of Virginia Health System

    Charlottesville

Washington, United States1 site
  • Evergreen Hospital Medical Center

    Kirkland

West Virginia, United States2 sites
  • University Physicians and Surgeons (dba Marshall Health)

    Huntington

  • West Virginia Clinical and Translational Science Institute

    Morgantown

Wisconsin, United States1 site
  • Medical College of Wisconsin

    Milwaukee

United States, by state

AlaskaAKMaineMEVermontVTNew HampshireNHWashington: 1 siteWA1MontanaMTNorth DakotaNDMinnesotaMNWisconsin: 1 siteWI1MichiganMINew York: 1 siteNY1Massachusetts: 6 sitesMA6Rhode IslandRIOregon: 1 siteOR1IdahoIDSouth DakotaSDIowaIAIllinois: 6 sitesIL6IndianaINOhio: 2 sitesOH2PennsylvaniaPANew Jersey: 1 siteNJ1ConnecticutCTCalifornia: 2 sitesCA2NevadaNVWyomingWYNebraskaNEMissouriMOKentucky: 1 siteKY1West Virginia: 2 sitesWV2Virginia: 1 siteVA1Maryland: 2 sitesMD2DelawareDEArizona: 3 sitesAZ3UtahUTColorado: 2 sitesCO2Kansas: 1 siteKS1ArkansasARTennesseeTNNorth Carolina: 1 siteNC1South CarolinaSCNew Mexico: 1 siteNM1OklahomaOKLouisianaLAMississippiMSAlabamaALGeorgia: 5 sitesGA5HawaiiHITexas: 4 sitesTX4Florida: 2 sitesFL2District of Columbia: 1 siteDC1
Fewer sitesMore sites

Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.

Drugs studied

The drug and biological interventions registered on this study, normalized to their RxNorm ingredient where possible.

Melantonin PlaceboMelatoninModafinil →Modafinil PlaceboSolriamfetol →Solriamfetol Placebo
Linked drugs open the directory filtered to KOLs working with them.clinicaltrials.gov ↗

Questions about NCT06404086

Each answer restates registry values shown on this page.

What is NCT06404086?

NCT06404086 is a phase 2 interventional trial sponsored by Duke University. It studies Melantonin Placebo, Melatonin, Modafinil, Modafinil Placebo and 2 more drugs in Hypersomnia, Long COVID and 2 more conditions.

Who leads NCT06404086?

The registry names Christina Barkauskas, MD (study chair, Duke Clinical Research Institute) and Susan Redline, MD MPH (study chair, Brigham and Women's Hospital) as overall officials.

Where does NCT06404086 run?

The registry lists 47 sites in 1 country. Every site with a stated country is in one country: United States.

Which drugs does NCT06404086 study?

The registered drug and biological interventions are Melantonin Placebo, Melatonin, Modafinil, Modafinil Placebo, Solriamfetol and Solriamfetol Placebo.

When did NCT06404086 end?

The registry lists a primary completion date of 31 Dec 2025 and a study completion date of 31 Dec 2025. The sponsor last updated the record on 22 Jan 2026.

Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 21 Nov 2026. Registry facts are shown as registered by the study sponsor; FindMyKOL does not interpret them.